Grade group system and plasma androgen receptor status in the first line treatment for metastatic castration resistant prostate cancer.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
05 05 2022
05 05 2022
Historique:
received:
22
01
2020
accepted:
06
01
2021
entrez:
5
5
2022
pubmed:
6
5
2022
medline:
10
5
2022
Statut:
epublish
Résumé
In localized prostate cancer (PCa), Grade Group (GG) and Gleason Score (GS) have a well-established prognostic role. In metastatic castration resistant prostate cancer (mCRPC), the prognostic role of GS and GG is less defined. In first-line treatment of mCRPC, androgen receptor (AR)-directed drugs (abiraterone acetate, enzalutamide) and docetaxel represent the referring options. There is no evidence that the GS/GG systems can add information to guide the choice between AR-directed drugs and docetaxel in the first-line setting of mCRPC. Nowadays there are no validated biomarkers, which define patients who may benefit or not from hormonal treatments or chemotherapy. Androgen receptor (AR) copy number variations (CNV) are predictive factors of poor response to abiraterone and enzalutamide. There are no available data about the association between AR CNV and GG. In this retrospective study, we analysed the association of the highest GG score with AR CNV and their impact on the clinical outcome of AR-directed drugs and docetaxel as first-line therapy for mCRPC patients. Patients benefit from docetaxel, abiraterone or enzalutamide regardless the GG. However, the presence of GG5 and AR CNV gain identifies a subgroup of patients with poor prognosis, which could benefit from front-line docetaxel instead of AR-directed drugs.
Identifiants
pubmed: 35513478
doi: 10.1038/s41598-022-10751-6
pii: 10.1038/s41598-022-10751-6
pmc: PMC9072417
doi:
Substances chimiques
Nitriles
0
Receptors, Androgen
0
Docetaxel
15H5577CQD
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
7319Informations de copyright
© 2022. The Author(s).
Références
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):296-303
pubmed: 28463149
Eur J Cancer. 2019 Jul;116:158-168
pubmed: 31200322
Ann Oncol. 2016 Apr;27(4):699-705
pubmed: 26609008
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
Eur J Cancer. 2019 Nov;121:7-18
pubmed: 31525487
Am J Surg Pathol. 2012 Jun;36(6):838-43
pubmed: 22592143
Br J Cancer. 2015 May 12;112(10):1717-24
pubmed: 25897673
JCO Precis Oncol. 2019 Dec;3:1-13
pubmed: 35100689
N Engl J Med. 2004 Oct 7;351(15):1513-20
pubmed: 15470214
Curr Opin Urol. 2016 Sep;26(5):488-92
pubmed: 27308734
Nat Rev Urol. 2010 Mar;7(3):136-42
pubmed: 20157302
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Am J Surg Pathol. 2005 Sep;29(9):1228-42
pubmed: 16096414
Eur Urol. 2018 Aug;74(2):146-154
pubmed: 29478736
Nat Med. 2016 Apr;22(4):369-78
pubmed: 26928463
Eur Urol Focus. 2016 Dec;2(5):499-505
pubmed: 28723515
Ann Oncol. 2017 Jul 01;28(7):1508-1516
pubmed: 28472366
Clin Cancer Res. 2017 Nov 15;23(22):6802-6811
pubmed: 28842510
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
Clin Cancer Res. 2017 Aug 15;23(16):4693-4703
pubmed: 28446506
Cancers (Basel). 2019 Nov 04;11(11):
pubmed: 31689899
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
JAMA Oncol. 2019 Jan 1;5(1):91-96
pubmed: 30326032
Nature. 2012 Jul 12;487(7406):239-43
pubmed: 22722839
Eur Urol. 2019 Jan;75(1):35-41
pubmed: 30554605
Lancet Oncol. 2012 Oct;13(10):983-92
pubmed: 22995653
Eur Urol. 2019 Mar;75(3):368-373
pubmed: 30773204